SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Orphan drug development is not taking off
3 references·3 citing·20 second hop
Orphan drug development is not taking off (2009)Orphan drug development is not taking offWhy rare diseases are an important medical and social issue (2008)Why rare diseases are an impo…Rare diseases and orphan drugs (2006)Rare diseases and orphan drugsOrphan drug development is progressing too slowly (2006)Orphan drug development is pr…Why we should care about ultra-rare disease (2016)Why we should care about ultr…Rare lung disease and orphan drug development (2013)Rare lung disease and orphan …An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences (2011)An Empirical Review of Major …Can Patents Deter Innovation? The Anticommons in Biomedical Research (1998)Universities as a Source of Commercial Technology: A Detailed Analysis of University Patenting, 1965–1988 (1998)The growth of patenting and licensing by U.S. universities: an assessment of the effects of the Bayh–Dole act of 1980 (2001)The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs (2012)Towards a sustainable system of drug development (2014)Evaluating The Impact Of The Orphan Drug Act’s Seven-Year Market Exclusivity Period (2018)Orphan drugs: legal aspects, current situation (2002)Orphan drugs and the NHS: should we value rarity? (2005)Exploring emerging technologies using metaphors – A study of orphan drugs and pharmacogenomics (2008)Orphan drugs: the regulatory environment (2012)Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs (2000)A journey of hope: lessons learned from studies on rare diseases and orphan drugs (2006)Drugs for exceptionally rare diseases: do they deserve special status for funding? (2005)The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review (2015)Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years (2010)The supportive care needs of parents with a child with a rare disease: results of an online survey (2016)Alone in a Crowd? Parents of Children with Rare Diseases’ Experiences of Navigating the Healthcare System (2018)Orphan drug legislation: lessons for neglected tropical diseases (2008)Predictors of orphan drug approval in the European Union (2008)Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007 (2010)
this work references cited by second hop

References

  • 2008Why rare diseases are an important medical and social issue621 cited
  • 2006Rare diseases and orphan drugs144 cited
  • 2006Orphan drug development is progressing too slowly70 cited

Cited by

  • 2011An Empirical Review of Major Legislation Affecting Drug Development: Past Experiences, Effects, and Unintended Consequences62 cited
  • 2013Rare lung disease and orphan drug development50 cited
  • 2016Why we should care about ultra-rare disease49 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work